Shi-Feng Lou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shi-Feng Lou has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Cheng Zhang
Medical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing, China
1 shared publication Dongyi Li
Department of Ophthalmology, Chongqing People's Hospital, University of Chinese Academy of Sciences, Chongqing, 400038, China
1 shared publicationGuo Chen
Medical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, Burns and Cobmined Injury, Army Medical University, Chongqing, China
1 shared publicationHan Yao
Medical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, Burns and Cobmined Injury, Army Medical University, Chongqing, China
1 shared publication- Hanqing Zeng
Central South University
1 shared publication - Jianchuan Deng
Department of Hematology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
1 shared publication
Latest Publications
- 17 June 2023
- Published by Springer Nature in Current Medical Science
- Vol. 43 (4) , 733-740
Donor-derived CD19 CAR-T Cells versus Chemotherapy Plus Donor Lymphocyte Infusion for Treatment of Recurrent CD19-positive B-ALL After Allogeneic Hematopoietic Stem Cell Transplantation
Objective This study aimed to compare the efficacy of anti-CD19 chimeric antigen receptor T cells (CAR-T cells) versus chemotherapy plus donor lymphocyte infusion (chemo-DLI) for treating relapsed CD19-positive B-cell acute lymphoblastic leukemia (B-ALL) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods Clinical data of 43 patients with B-ALL who relapsed after allo-HSCT were retrospectively analyzed. Twenty-two patients were treated with CAR-T cells (CAR-T group), and 21 with chemotherapy plus DLI (chemo-DLI group). The complete remission (CR) and minimal residual disease (MRD)-negative CR rates, leukemia-free survival (LFS) rate, overall survival (OS) rate, and incidence of acute graft-versus-host disease (aGVHD), cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were compared between the two groups. Results The CR and MRD-negative CR rates in the CAR-T group (77.3% and 61.5%) were significantly higher than those in the chemo-DLI group (38.1% and 23.8%) (P=0.008 and P=0.003). The 1- and 2-year LFS rates in the CAR-T group were superior to those in the chemo-DLI group: 54.5% and 50.0% vs. 9.5% and 4.8% (P=0.0001 and P=0.00004). The 1- and 2-year OS rates in the CAR-T versus chemo-DLI group were 59.1% and 54.5% vs. 19% and 9.5% (P=0.011 and P=0.003). Six patients (28.6%) with grade 2–4 aGVHD were identified in the chemo-DLI group. Two patients (9.1%) in the CAR-T group developed grade 1–2 aGVHD. Nineteen patients (86.4%) developed CRS in the CAR-T group, comprising grade 1–2 CRS in 13 patients (59.1%) and grade 3 CRS in 6 patients (27.3%). Two patients (9.1%) developed grade 1–2 ICANS. Conclusion Donor-derived anti-CD19 CAR-T-cell therapy may be better, safer, and more effective than chemo-DLI for B-ALL patients who relapse after allo-HSCT.
- 17 June 2023
- Published by Springer Nature in Current Medical Science
- Vol. 43 (4) , 733-740
Donor-derived CD19 CAR-T Cells versus Chemotherapy Plus Donor Lymphocyte Infusion for Treatment of Recurrent CD19-positive B-ALL After Allogeneic Hematopoietic Stem Cell Transplantation
Objective This study aimed to compare the efficacy of anti-CD19 chimeric antigen receptor T cells (CAR-T cells) versus chemotherapy plus donor lymphocyte infusion (chemo-DLI) for treating relapsed CD19-positive B-cell acute lymphoblastic leukemia (B-ALL) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods Clinical data of 43 patients with B-ALL who relapsed after allo-HSCT were retrospectively analyzed. Twenty-two patients were treated with CAR-T cells (CAR-T group), and 21 with chemotherapy plus DLI (chemo-DLI group). The complete remission (CR) and minimal residual disease (MRD)-negative CR rates, leukemia-free survival (LFS) rate, overall survival (OS) rate, and incidence of acute graft-versus-host disease (aGVHD), cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were compared between the two groups. Results The CR and MRD-negative CR rates in the CAR-T group (77.3% and 61.5%) were significantly higher than those in the chemo-DLI group (38.1% and 23.8%) (P=0.008 and P=0.003). The 1- and 2-year LFS rates in the CAR-T group were superior to those in the chemo-DLI group: 54.5% and 50.0% vs. 9.5% and 4.8% (P=0.0001 and P=0.00004). The 1- and 2-year OS rates in the CAR-T versus chemo-DLI group were 59.1% and 54.5% vs. 19% and 9.5% (P=0.011 and P=0.003). Six patients (28.6%) with grade 2–4 aGVHD were identified in the chemo-DLI group. Two patients (9.1%) in the CAR-T group developed grade 1–2 aGVHD. Nineteen patients (86.4%) developed CRS in the CAR-T group, comprising grade 1–2 CRS in 13 patients (59.1%) and grade 3 CRS in 6 patients (27.3%). Two patients (9.1%) developed grade 1–2 ICANS. Conclusion Donor-derived anti-CD19 CAR-T-cell therapy may be better, safer, and more effective than chemo-DLI for B-ALL patients who relapse after allo-HSCT.
- Open Access
- 1 January 2023
- Published by Beijing Clintile Information Technology (Hong Kong) Co., Limited in Diseases & Research
- Vol. 3 (1) , 55-64
Multiparameter Flow Cytometry: An Important Auxiliary Tool for The Diagnosis and Differential Diagnosis of Myelodysplastic Neoplasms
Multiparameter flow cytometry (MFC) shows promise in the diagnosis and differential diagnosis of myelodysplastic neoplasms (MDS). By identifying abnormal immunophenotypes of different cell lineages in bone marrow (BM) cells, MFC can aid in the differential diagnosis of some bone marrow failure diseases. Several flow cytometry scoring systems have been established based on current parameters, but there is still no specific immunophenotype available for the diagnosis of MDS. Morphological examination of cells remains the gold standard for MDS diagnosis. In the future, identifying specific cell immunophenotypes may improve MDS diagnosis and alter the use of MFC. MFC may also provide a solution for tracking the evolution of specific abnormal hematopoietic clones in MDS.
- 1 January 2023
- Published by Beijing Clintile Information Technology (Hong Kong) Co., Limited in Diseases & Research
- Vol. 3 (1) , 55-64
Open AccessMultiparameter Flow Cytometry: An Important Auxiliary Tool for The Diagnosis and Differential Diagnosis of Myelodysplastic Neoplasms
Multiparameter flow cytometry (MFC) shows promise in the diagnosis and differential diagnosis of myelodysplastic neoplasms (MDS). By identifying abnormal immunophenotypes of different cell lineages in bone marrow (BM) cells, MFC can aid in the differential diagnosis of some bone marrow failure diseases. Several flow cytometry scoring systems have been established based on current parameters, but there is still no specific immunophenotype available for the diagnosis of MDS. Morphological examination of cells remains the gold standard for MDS diagnosis. In the future, identifying specific cell immunophenotypes may improve MDS diagnosis and alter the use of MFC. MFC may also provide a solution for tracking the evolution of specific abnormal hematopoietic clones in MDS.
- Open Access
- 28 March 2022
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 608, 73-81
The hsa-miR-214-3p/ATGL axis regulates aberrant lipolysis to promote acute myeloid leukemia progression via PPARα in vitro
- 28 March 2022
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 608, 73-81
Open AccessThe hsa-miR-214-3p/ATGL axis regulates aberrant lipolysis to promote acute myeloid leukemia progression via PPARα in vitro
- 1 September 2016
- Published by Elsevier in Leukemia Research
- Vol. 48, 6-10
Allogeneic hematopoietic stem cell transplantation following donor CIK cell infusion: A phase I study in patients with relapsed/refractory hematologic malignancies
- 1 September 2016
- Published by Elsevier in Leukemia Research
- Vol. 48, 6-10
Allogeneic hematopoietic stem cell transplantation following donor CIK cell infusion: A phase I study in patients with relapsed/refractory hematologic malignancies